pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,806 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1860Endpoints1445Fierce Biotech764BioSpace754BioPharma Dive548raps249onclive165fda recalls
therapy area
allOncology12884Rare Disease3330Immunology3020Cardiology2847Hematology2294Pulmonology2253Vaccines
  • Xenon shares tumble up to 30% after pausing depression trial over neuropsychiatric events
    Xenon Pharmaceuticals announced it is pausing enrollment in its depression trial for the drug azetukalner after neuropsychiatric adverse events emerged that were not observed in earlier testing. A…
    BioPharma Dive · 2mo agoNegative readoutNegative↗ source
  • Roche opens new research center in Boston, expanding its local presence
    Roche announced the opening of a new research facility in Boston, adding to its existing operations in the city. The center will focus on early-stage drug discovery and will house several hundred…
    STAT · 2mo agoPositive↗ source
← prev
page 35 of 113
next →
119
fda medwatch114
globenewswire health73
fda press61
1853
Psychiatry & CNS1230
Ophthalmology1131
Endocrinology & Metabolism806
Pain790
Nephrology783
  • Electra Therapeutics raises $350M in biotech IPO, fueling rare disease drug development
    Electra Therapeutics completed a $350 million initial public offering, becoming the 21st biotechnology company to go public in 2026. The strong demand for its shares highlights continued investor a…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Trump announces GENEROUS model, securing pharma deals to cut Medicaid drug prices
    President Trump announced a new initiative called the GENEROUS model that is intended to lower drug prices for state Medicaid programs. The program will involve all 50 states, Washington, D.C., an…
    STAT · 2mo agoDealNeutral↗ source
  • GSK adds two China cancer-therapy licensing deals, keeping pace with industry partnership surge
    BioPharma Dive's new visualization series recapped recent activity, spotlighting GSK's licensing agreements in China and the market response. Since the start of 2025, GSK has signed five deals wit…
    BioPharma Dive · 2mo agoDealNeutral↗ source
  • Ultragenyx prices Sanfilippo gene therapy at $4 million as it gains a second FDA approval; Bristol Myers halts Orum cancer drug
    The FDA approved Fayuvi, the first gene therapy for Sanfilippo syndrome Type A, with a list price of $3.95 million. This marks Ultragenyx's second gene‑therapy approval since August, earning sella…
    BioPharma Dive · 2mo agoApprovalNeutral↗ source
  • U.S. drafts new investment rules to keep pharma licensing deals with China viable
    The United States is drafting new guidelines that would govern how American investors can fund Chinese biotech and pharmaceutical companies. The proposed framework is intended to address national‑s…
    STAT · 2mo agoRegulatoryPositive↗ source
  • Sudan civil war forces cancer patients to endure hazardous journeys for treatment
    Medical missionary Tom Catena has run the Mother of Mercy hospital in the Nuba Mountains for over a decade, but the ongoing civil war has crippled Sudan’s health system. The remote facility, the la…
    STAT · 2mo agoNegative↗ source
  • Spectra Medical recalls Sodium Chloride Flush ampules due to serious safety risk
    Spectra Medical Devices has issued a recall of its Sodium Chloride Injection 0.9% USP 10 mL flush ampules that were manufactured by Huons Co., Ltd. The FDA classified the recall as the most serious…
    fda medwatch · 2mo agoCRLNegative↗ source
  • HCA Healthcare sues Independence Blue Cross over $345,000 in unpaid Texas hospital claims
    Several Texas hospitals owned by HCA Healthcare have filed a lawsuit against Independence Blue Cross, a Philadelphia‑based insurer, seeking more than $345,000 in unpaid medical claims dating back r…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Doctors urged to tell patients Asian glow signals health risk, not harmless quirk
    Brian Zhang, a second-year medical student at Stanford and student body president, wrote an opinion piece urging doctors to discuss the so-called "Asian glow" with patients. The facial flushing th…
    STAT · 2mo agoNeutral↗ source
  • FDA updates instructions for NOxBOXi nitric oxide delivery system after leak risk identified
    The FDA has issued a correction for the NOxBOXi nitric oxide delivery system with the NOxMixer module after discovering that the device can leak oxygen during inhaled nitric oxide therapy. The age…
    fda medwatch · 2mo agoCRLNeutral↗ source
  • Panel discusses how questions about health equity shape public trust in science
    Anil Oza reported that he participated in a National Academies of Science roundtable focused on population health and how research communication influences public trust. The discussion highlighted…
    STAT · 2mo agoNeutral↗ source
  • IN8bio appoints Oxana Polyakova as senior vice president of R&D
    IN8bio announced a new senior vice president for research and development. Oxana Polyakova joins the company after serving as chief scientific officer at LAVA Therapeutics. Her background in drug…
    STAT · 2mo agoPositive↗ source
  • Geriatrician urges careful use of AI predictions for older patients
    Artificial intelligence tools are being added to electronic health records to flag patients at risk for conditions such as sepsis, falls or even death. The ease of integration has led many clinicia…
    STAT · 2mo agoNeutral↗ source
  • Rise in Young Men Seeking Cosmetic Surgery Driven by Social Media Influence, Surgeon Observes
    A board‑certified plastic surgeon in Boston reports that more young men are now filling her waiting room than ever before, making men the fastest‑growing group in aesthetic procedures. Procedures…
    STAT · 2mo agoNeutral↗ source
  • GF Blends recalls AIP flour and flatbread mixes over undeclared wheat gluten
    GF Blends announced a recall of its Truly AIP All Purpose Flour and Bread Mix and the EAT G.A.N.G.S.T.E.R. Flat Bread Pizza Mix because testing found undeclared wheat gluten. The products were mad…
    fda recalls · 2mo agoRegulatoryNegative↗ source
  • North Immunology to go public via reverse merger with Aethlon, targeting eczema market
    North Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • England's NHS to fund AstraZeneca's Enhertu for metastatic breast cancer after U.K.-U.S. pricing pact
    English health authorities have agreed to provide AstraZeneca's breast cancer drug Enhertu through the NHS, ending a multi-year dispute over its availability. The decision will make the drug acces…
    STAT · 2mo agoDealPositive↗ source
  • Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic disease
    Novo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Lisata acquires Marea Therapeutics, securing $225M financing to advance two mid-stage drugs
    Lisata Therapeutics completed a stock-for-stock acquisition of biotech startup Marea Therapeutics. The transaction includes a $225 million financing round led by existing backers such as Forbion,…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • FDA staffing shortage limits ability to hire new employees, raising concerns for health-care oversight
    STAT's D.C. Diagnosis newsletter reports that the FDA is experiencing a staffing bottleneck, with too few current employees to bring on additional hires. The shortage could slow the agency's capac…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Study finds purer fentanyl will not curb U.S. overdose deaths
    A new study highlighted that increasing the purity of fentanyl is unlikely to lower the number of overdose fatalities in the United States. Researchers noted that while purer fentanyl may be more…
    STAT · 2mo agoNegative↗ source
  • Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival Endpoint
    Sellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
    STAT · 2mo agoNegative↗ source
  • Roche partners with Dualitas Therapeutics in up to $1 billion deal to screen bispecific antibodies for immune diseases
    Roche has committed $36.5 million up front to biotechnology startup Dualitas Therapeutics under a research partnership that could total up to $1 billion in milestone payments and royalties. The agr…
    BioPharma Dive · 2mo agoDealPositive↗ source